GDNF released from encapsulated cells suppresses seizure activity in the epileptic hippocampus.
(2009) In Experimental Neurology 216. p.413-419- Abstract
- To date, a variety of pharmacological treatments exists for patients suffering epilepsy, but systemically administered drugs offer only symptomatic relief and often cause unwanted side effects. Moreover, available drugs are not effective in one third of the patients. Thus, more local and more effective treatment strategies need to be developed. Gene therapy-based expression of endogenous anti-epileptic agents represents a novel approach that could interfere with the disease process and result in stable and long-term suppression of seizures in epilepsy patients. We have reported earlier that direct in vivo viral vector-mediated overexpression of the glial cell line-derived neurotrophic factor (GDNF) in the rat hippocampus suppressed... (More)
- To date, a variety of pharmacological treatments exists for patients suffering epilepsy, but systemically administered drugs offer only symptomatic relief and often cause unwanted side effects. Moreover, available drugs are not effective in one third of the patients. Thus, more local and more effective treatment strategies need to be developed. Gene therapy-based expression of endogenous anti-epileptic agents represents a novel approach that could interfere with the disease process and result in stable and long-term suppression of seizures in epilepsy patients. We have reported earlier that direct in vivo viral vector-mediated overexpression of the glial cell line-derived neurotrophic factor (GDNF) in the rat hippocampus suppressed seizures in different animal models of epilepsy. Here we explored whether transplantation of encapsulated cells that release GDNF in the hippocampus could also exert a seizure-suppressant effect. Such ex vivo gene therapy approach represents a novel, more clinically safe approach, since the treatment could be terminated by retrieving the transplants from the brain. We demonstrate here that encapsulated cells, which are genetically modified to produce and release GDNF, can suppress recurrent generalized seizures when implanted into the hippocampus of kindled rats. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1289375
- author
- Kanter Schlifke, Irene LU ; Fjord-Larsen, Lone ; Kusk, Philip ; Ängehagen, Mikael LU ; Wahlberg, Lars and Kokaia, Merab LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Experimental Neurology
- volume
- 216
- pages
- 413 - 419
- publisher
- Elsevier
- external identifiers
-
- wos:000264606600022
- pmid:19162016
- scopus:62349124875
- pmid:19162016
- ISSN
- 0014-4886
- DOI
- 10.1016/j.expneurol.2008.12.021
- language
- English
- LU publication?
- yes
- id
- 7954a323-2df6-479e-a898-fbc5527974d7 (old id 1289375)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19162016?dopt=Abstract
- date added to LUP
- 2016-04-04 07:52:53
- date last changed
- 2022-01-29 02:43:36
@article{7954a323-2df6-479e-a898-fbc5527974d7,
abstract = {{To date, a variety of pharmacological treatments exists for patients suffering epilepsy, but systemically administered drugs offer only symptomatic relief and often cause unwanted side effects. Moreover, available drugs are not effective in one third of the patients. Thus, more local and more effective treatment strategies need to be developed. Gene therapy-based expression of endogenous anti-epileptic agents represents a novel approach that could interfere with the disease process and result in stable and long-term suppression of seizures in epilepsy patients. We have reported earlier that direct in vivo viral vector-mediated overexpression of the glial cell line-derived neurotrophic factor (GDNF) in the rat hippocampus suppressed seizures in different animal models of epilepsy. Here we explored whether transplantation of encapsulated cells that release GDNF in the hippocampus could also exert a seizure-suppressant effect. Such ex vivo gene therapy approach represents a novel, more clinically safe approach, since the treatment could be terminated by retrieving the transplants from the brain. We demonstrate here that encapsulated cells, which are genetically modified to produce and release GDNF, can suppress recurrent generalized seizures when implanted into the hippocampus of kindled rats.}},
author = {{Kanter Schlifke, Irene and Fjord-Larsen, Lone and Kusk, Philip and Ängehagen, Mikael and Wahlberg, Lars and Kokaia, Merab}},
issn = {{0014-4886}},
language = {{eng}},
pages = {{413--419}},
publisher = {{Elsevier}},
series = {{Experimental Neurology}},
title = {{GDNF released from encapsulated cells suppresses seizure activity in the epileptic hippocampus.}},
url = {{http://dx.doi.org/10.1016/j.expneurol.2008.12.021}},
doi = {{10.1016/j.expneurol.2008.12.021}},
volume = {{216}},
year = {{2009}},
}